Orville Campbell, MD, MBA Chief Executive Officer

Orville C. Campbell, MD, MBA is a physician executive who has led the development of nephrology, dialysis, primary care, cardiovascular risk, correctional healthcare, utilization management, and population health programs. He has developed high functioning inter-professional teams that integrate physicians, advanced practice clinicians, pharmacists, behavioral health professionals, and care coordinators.

Dr. Campbell served as Epidemiologist, Strategist, and Performance Measurements Lead for the Behavioral Health & Wellness Division of Metro Public Health Department of Nashville and Davidson County, where he led a high impact team of epidemiologists and research analysts, divisional level strategy, analytics, and clinical performance infrastructure across nine programmatic areas. He played a central role in informing the design, development, and implementation of a countywide Opioid System of Care. He founded Nashville Adult Opioid Overdose and Suicide Fatality Review Panel, architected the division’s five year strategic plan, advanced executive dashboards and KPI frameworks, and drives cross-sector collaboration with health systems, academic partners, faith-based organizations, and public safety agencies.

Dr. Campbell has demonstrated the ability to co-design clinical models with technical teams, operationalize performance metrics, supervise and develop physician leaders, and embed specialty services seamlessly within broader care health systems. His career reflects a consistent pattern of building from concept to execution while managing clinical risk, mentoring clinicians, modernizing infrastructure, and establishing cultures of accountability, innovation, curiosity, continuous improvement, regulatory readiness, and safety.

He has served on advisory boards for Gambro Healthcare (Western Division), Shire Pharmaceuticals, and Abbott Pharmaceuticals, providing senior clinical guidance on quality, strategy, and regulatory aligned medical communications. He delivered performance recommendations across a 276-clinic dialysis footprint to drive stronger clinical consistency and quality metrics at scale. He supported Shire’s Fosrenol launch planning, including FDA facing packaging/compliance input and review of educational and promotional materials. He also advised on CME and promotional programming to improve provider engagement and evidence-based adoption. Dr. Campbell was selected as a national speaker for Amgen, Genzyme, and Novartis, presenting on end stage kidney disease, anemia, hypertension, and metabolic bone disease.